CTORCitius Oncology Inc. Common Stock

NAS · US · Financial Services · Drug Manufacturers - Specialty & Generic · citiusonc.com

0.7438USD-1.16%Mkt Cap: 78.66M $P/E: —3d ago

Citius Oncology, Inc. focuses on the development and commercialization of targeted oncology therapies. It also engages in the development of LYMPHIR, an orphan indication for the treatment of adult patients with relapsed…

Industry Peers

Drug Manufacturers - Specialty & Generic

Screen all

MRK

MERCK Kommanditgesellschaft auf Aktien

$65.19BUSDP/E 23.7

TAK

Takeda Pharmaceutical Co. Ltd.

$58.06BUSD

HLN

Haleon plc American Depositary Shares (Each representing two Ordinary Shares)

$43.98BUSDP/E 20.4

TEVA

Teva Pharmaceutical Industries Limited

United Therapeutics Corporation

Swedish Orphan Biovitrum AB

Neurocrine Biosciences, Inc.

$15.51BUSDP/E 22.3

ELAN

Elanco Animal Health Incorporat

$11.98BUSD

RDY

Dr. Reddy's Laboratories Ltd

Hims & Hers Health, Inc.

$7.88BUSD

LNTH

Lantheus Holdings Inc

$6.53BUSDP/E 23.9

AMRX

Amneal Pharmaceuticals, Inc. Class A

Kiniksa Pharmaceuticals, Ltd.

$6.08BUSDP/E 79.8

Key Statistics

Company

Market Cap78.66M $

Enterprise Value85.76M $

Revenue (TTM)5.61M $

Gross Profit4.49M $

Net Income (TTM)-24.76M $

Revenue/Share0.0670 USD

Last Price0.7438 USD

Fiscal Year EndSep 2025

MR QuarterMar 2026

Employees—

CountryUS

SectorFinancial Services

IndustryDrug Manufacturers - Specialty & Generic

ISIN—

Valuation

P/E (Trailing)—

P/E (Forward)—

PEG—

EV/EBITDA—

EV/Revenue15.28

P/S14.31

P/B1.41

EPS (TTM)-0.48

EPS (Forward)—

52W Range

0.491014% of range2.250

52W High2.250 USD

52W Low0.4910 USD

Profitability

Gross Margin80.07%

Oper. Margin-1716.17%

EBITDA Margin0.00%

Profit Margin0.00%

ROE-55.19%

ROA-24.53%

Growth

Revenue Growth—

Earnings Growth—

Cash Flow & Leverage

Operating CF-5.49M $

CapEx (TTM)5.75M $

FCF Margin-420.87%

FCF Yield-30.02%

Net Debt1.17M $

Net Debt/EBITDA—

Balance Sheet

Debt/Equity0.08

Current Ratio0.50

Quick Ratio0.06

Book Value/Sh0.5370 USD

Cash/Share0.0280 USD

Dividends

Fwd Div Rate—

Trail. Div Rate0.0000 USD

Div. Yield—

5Y Avg Yield—

Payout Ratio0.00%

Ex-Div Date—

Pay Date—

Analyst Consensus

Rating2.0 (Buy)

Strong BuyBuyHoldSellStr. Sell

Target (Mean)4.000 USD

Upside (mean)+437.8%

Target Range4.000 USD – 4.000 USD

# Analysts1

Ownership

Shares Out.105.76M

Float17.72M

Insiders77.51%

Institutions15.21%

Short Interest

Short Ratio7.2d

Short % Float2.38%

Short % Out.0.43%

Shares Short399.41K

Short (prev mo.)453.35K

Technical

SMA 500.6796 (+9.4%)

SMA 2000.9311 (-20.1%)

Beta3.49

S&P 52W Chg18.16%

Avg Vol (30d)103.32K

Avg Vol (10d)105.29K

Technical Indicators

RSI (14)52.9

MACD0.0345

MACD Signal0.0254

MACD Hist.+0.0091

BB Upper0.9105 USD

BB Middle0.6888 USD

BB Lower0.4671 USD

BB Width64.37%

ATR (14)0.0814 USD

Vol Ratio (20d)0.09x